Lawrence Corey
Fred Hutchinson Cancer Center
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
SARS-CoV-2 and COVID-19 Research
Strong evidence · 9 supporting papers · latest 2026
HIV Research and Treatment
Strong evidence · 14 supporting papers · latest 2026
HIV/AIDS Research and Interventions
Strong evidence · 5 supporting papers · latest 2026
HIV/AIDS drug development and treatment
Strong evidence · 6 supporting papers · latest 2026
Vaccine Coverage and Hesitancy
Strong evidence · 2 supporting papers · latest 2025
COVID-19 Clinical Research Studies
Strong evidence · 8 supporting papers · latest 2026
Herpesvirus Infections and Treatments
Strong evidence · 1 supporting paper · latest 2025
Virus-based gene therapy research
Strong evidence · 1 supporting paper · latest 2025
Publications (26)
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
2025DOIPMID 41053137
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection
2026DOIPMID 41279611
Limitations of acyclovir and identification of potent HSV antivirals using 3D bioprinted human skin equivalents
2025DOIPMID 41102222
How HIV research drives health innovation in multiple diseases
2025DOIPMID 41136629
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
2025DOI
Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial
2025DOIPMID 41210956
VRC01 Exerted Differential Pressure on HIV-1 Envelope From Subtypes B and C That Continued in the First Weeks Postdiagnosis in the Antibody Mediated Prevention Trials
2026DOIPMID 42708883
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data
2026DOI
Relative efficacy, safety and immunogenicity of bivalent versus monovalent COVID-19 mRNA booster vaccines: a randomized trial
2026DOIPMID 42779880
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine
2026DOIPMID 42000737
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
2026DOI
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine
2025DOIPMID 41137757
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
2026DOI
Priming of Multiple HIV Neutralizing B Cell Precursors in Humans
2026DOIPMID 42145593
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Fred Hutchinson Cancer Center
Source: OpenAlex · retrieved 2026-09-29
Source: ScienceWe Extractor · retrieved 2026-09-27